In a comprehensive meta-analysis that did not incorporate any hepatocellular carcinoma (HCC) trials, the most commonly affected target organs by immune-related adverse events (irAEs) during cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibition were the skin (44%) and the gastrointestinal tract (35%) (7). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.